Methazolamide
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Methazolamide: From Carbonic Anhydrase Inhibitor to Primary Hereditary Glaucoma
One-Sentence Summary
Methazolamide (DrugBank DB00703) is a carbonic anhydrase inhibitor; its original indication record is not available in this database and the drug is not currently marketed in Taiwan. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma, but this specific evidence pack currently contains 0 clinical trials and 0 publications directly supporting the pairing — the high score reflects the drug’s known pharmacological class rather than confirmed new evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in database (drug not marketed in Taiwan; DrugBank original-indication field is empty) |
| Predicted New Indication | Primary Hereditary Glaucoma |
| TxGNN Prediction Score | 99.83% |
| Evidence Level | L5 (no clinical trials or literature retrieved for this drug–disease pair) |
| Taiwan Market Status | ✗ 未上市 (Not marketed) |
| License Count | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not on file for this record (original_moa: [Data Gap]). Based on known pharmacology, methazolamide belongs to the carbonic anhydrase inhibitor (CAI) class, alongside acetazolamide and dorzolamide. In several markets, methazolamide itself is already approved for glaucoma — CAIs lower intraocular pressure by inhibiting carbonic anhydrase in the ciliary body, reducing aqueous humor production. This is a well-established, mechanistically direct route to treating glaucoma, not a novel or speculative pathway.
Given this, the TxGNN prediction most plausibly reflects the model rediscovering an already-known pharmacological use of the drug class, rather than surfacing new evidence. The empty original_indications field in this dataset is more likely a local data-collection gap than evidence that methazolamide has no established ocular indication.
Because no clinical trials or publications specific to methazolamide + primary hereditary glaucoma were retrieved in this search cycle, this prediction should be treated as mechanistically credible but currently evidence-thin within this evidence pack, and would benefit from a broader literature search (e.g., including historical glaucoma-specific terms not captured by the current disease-name query).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Methazolamide has 0 registered licenses and is not currently marketed in Taiwan, so no product/authorization details are available.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are all currently unavailable — TFDA label data is flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score (99.83%) and known CAI-class mechanism make this a plausible signal, but no clinical trial or literature evidence specific to methazolamide in glaucoma exists in this evidence pack, and safety/labeling data is completely unavailable — a Blocking-severity gap that prevents even an initial safety screen (S1).
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — DG001, Blocking
- DrugBank-sourced mechanism of action and original indication confirmation — DG002
- A widened literature/clinical-trial search using glaucoma-specific synonyms, since methazolamide’s established ocular use suggests the current 0-result query may be missing existing evidence
- Note: two other TxGNN candidates for this drug (congestive heart failure — 6 supporting papers, preclinical/review only; acute pulmonary heart disease — no evidence, recommendation Hold) exist in this evidence pack but are outside the scope of this single-indication report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.